Showing 661-670 of 1478 results for "".
- RINVOQ (Upadacitinib) Meets Primary Endpoint in Phase 2 Clinical Trial of Vitiligo, Program Advances to Phase 3https://practicaldermatology.com/news/upadacitinib-rinvoq-meets-primary-endpoint-in-phase-2-clinical-trial-of-vitiligo-program-advances-to-phase-3/2462064/Abbvie's upadacitinib (RINVOQ) met the primary endpoint of percent change from baseline in Facial Vitiligo Area Scoring Index (F-VASI) at week 24 with 11 mg and 22 mg doses versus placebo in adults with non-segmental vitiligo (NSV), according to data presented at the European Academy of Derma
- Nemolizumab Performs Well in AD, PNhttps://practicaldermatology.com/news/nemolizumab-performs-well-in-ad-pn/2462061/Galderma’s nemolizumab performed well in three pivotal phase III trials in atopic dermatitis (AD) and prurigo nodularis (PN), according to late-breaking data presented at the 2023 European Academy of Dermatology and Venereology (EADV) congress in Berlin. Nemolizuma
- InMode: Employees in Isreal Are Safehttps://practicaldermatology.com/news/inmode-employees-in-isreal-are-safe/2462053/InMode Ltd. has affirmed the safety of the employees at the Company's Yokneam, Israel headquarters and does not anticipate any interruption in productionas a result of the Israel-Hamas War, "InMode is committed to supporting all customers, distributors, employees, and
- Professor Alexander Egeberg Named Head of Global Medical Affairs at Leo Pharmahttps://practicaldermatology.com/news/professor-alexander-egeberg-named-will-head-of-global-medical-affairs-at-leo-pharma/2462050/Professor Alexander Egeberg is LEO Pharma’s new Vice President, Head of Global Medical Affairs. The announcement was made ahead of the upcoming 32nd European Academy of Dermatology and Venereology (EADV) Congress. Alexander Egeberg joins LEO Pharma from his role as professor of de
- DecisionDx-Melanoma Outperforms MSKCC Nomogram in Predicting Sentinel Lymph Node Positivity in Melanomahttps://practicaldermatology.com/news/decisiondx-melanoma-outperforms-mskcc-nomogram-in-predicting-sentinel-lymph-node-positivity-in-melanoma/2462044/Castle Biosciences, Inc.’s DecisionDx-Melanoma outperformed a nomogram developed at the Memorial Sloan Kettering Cancer Center (MSKCC) in predicting the risk of sentinel lymph node (SLN) positivity in patients with cutaneous melanoma (CM), according to a new study in
- Measuring ctDNA May Lead to Alternative Treatment Options and Better Outcomes in Advanced Melanomahttps://practicaldermatology.com/news/measuring-ctdna-may-lead-to-alternative-treatment-options-and-better-outcomes-in-advanced-melanoma/2462040/Circulating tumor DNA (ctDNA) is emerging as a blood-based biomarker for many solid tumor types, including melanoma. A new study found that measuring ctDNA in the blood of patients with BRAF wild-type (BRAF WT) s
- AD Pipeline Update: FDA Rejects Lilly’s Lebrikizumab Due to Third-Party Manufacturing Issueshttps://practicaldermatology.com/news/ad-pipeline-update-fda-rejects-lillys-lebrikizumab-due-to-third-party-manufacturing-issues/2462037/The U.S. Food and Drug Administration (FDA) did not approve Eli Lilly's lebrikizumab biologic license application (BLA) for the treatment of moderate-to-severe atopic dermatitis due to findings during an inspection of a contract manufacturer. The letter cited findings
- Industry Vet Brent Hauser Named President, International at Cuterahttps://practicaldermatology.com/news/industry-vet-brent-hauser-named-president-international-at-cutera/2462034/Brent Hauser is the new President, International, at Cutera, Inc. Mr. Hauser will report directly to Taylor Harris, Cutera’s Chief Executive Officer, and will be responsible for commercial performance in existing international markets, expansion into new geographies, and the inter
- CeraVe Funds New Derm Residency Position at George Washington Universityhttps://practicaldermatology.com/news/cerave-funds-new-derm-residency-position-at-george-washington-university/2462012/CeraVe is partnering with George Washington University to support a newly approved Accreditation Council for Graduate Medical Education (ACGME) residency spot in the school's Department of Dermatology Resident Program, slated to begin on July 1, 2024. "
- Positive Topline Results Seen for Roflumilast Cream 0.05% in Young Kidshttps://practicaldermatology.com/news/positive-topline-results-seen-for-roflumilast-cream-005-in-young-kids/2462010/Arcutis Biotherapeutics, Inc.’s roflumilast cream 0.05% met all primary endpoint and all secondary endpoints in children aged 2 to 5 years with mild to moderate atopic dermatitis (AD), according to results from the INTEGUMENT-PED pivotal Phase 3 trial. In